– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies t ...

Fair Value of Warrant Liabilities - Fair value of warrant liabilities as of September 30, 2024: $77,884, compared to $806,655 as of December 31, 2023[97] - Change in fair value of warrant liabilities for the nine months ended September 30, 2024: $(728,771), compared to $305,972 for the same period in 2023[97] Lattice Model Parameters - Risk-free interest rate used in Lattice model: 3.91% as of September 30, 2024, compared to 4.25% as of December 31, 2023[98] - Remaining expected term of Private Warrants: 1.21 years as of September 30, 2024, compared to 1.96 years as of December 31, 2023[98] - Expected volatility used in Lattice model: 123.60% as of September 30, 2024, compared to 89.00% as of December 31, 2023[98] - Stock price on valuation date: $1.44 as of September 30, 2024, compared to $5.15 as of December 31, 2023[98] - Exercise price of Private Warrants: $11.50 as of September 30, 2024 and December 31, 2023[98] Stock Options and Vesting - Grant of 730,000 nonqualified stock options to non-executive employees on October 30, 2024, with an exercise price of $1.16[99] - Vesting periods for granted stock options range from sixteen months to thirty-eight months[99] Market Risk Disclosures - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[175]

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually O ...

CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking ...

CUPERTINO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, ...

Core Insights - Brilaroxazine is a newly discovered chemical entity with strong affinity and selectivity for serotonin and dopamine receptors, relevant for conditions such as schizophrenia, psoriasis, and interstitial lung diseases like pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) [1][4] Patent and Regulatory Developments - The European Patent Office has granted patent EP3244896 for brilaroxazine, covering its use in treating PH and PAH, including in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) [8] - Similar patents have been granted in key markets including the United States, China, and Japan [2] Clinical Data and Efficacy - Brilaroxazine has shown a favorable safety and tolerability profile in over 800 subjects across multiple clinical trials, with significant reductions in proinflammatory biomarkers in a Phase 3 study for schizophrenia [4][13] - The global Phase 3 RECOVER-1 trial demonstrated that brilaroxazine met all primary and secondary endpoints, showing statistically significant reductions in major symptom domains and proinflammatory cytokines at week 4 [4] - Positive data from a drug-drug interaction study indicated no clinically significant interactions with CYP3A4 inhibitors [4] Future Development Plans - The company plans to explore brilaroxazine for additional neuropsychiatric indications, including bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) [4]

- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of PH/PAH "This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Brilaroxazine Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptor ...

CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 The investigation concerns whether Reviva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On Apri ...